Clinical Success of the TIL Technology Platform in Solid Tumors

Time: 1:30 pm
day: Conference Day 1


  • Highlight advantages of polyclonal TIL MOA for solid tumors
  • Improving access to TIL using a proprietary, scalable, commerciallyviable manufacturing process
  • Review positive clinical data for TIL in metastatic melanoma and other solid tumor types
  • Explore next-generation approaches